By Adrienne B. Mendoza, MHA – LinkedIn –
The infrastructure behind Advanced Therapies is deeply rooted in global supply chains, and that foundation is shifting.
With new U.S. tariffs taking effect and global trade tensions escalating, cell and gene therapy programs are facing renewed pressure to protect continuity — the seamless, dependable flow of materials, manufacturing, and logistics that moves therapies from concept to care.
Your product may not be on a tariff list. But if your critical inputs are, your program could still feel the impact.
